Strategic funding ILiAD Biotechnologies has recently secured substantial Series B funding of 115 million, signaling strong investor confidence and potential for accelerated clinical development and expanded partnerships.

Phase 3 readiness As a phase 3 ready clinical-stage company focused on pertussis and respiratory diseases, ILiAD presents opportunities for CROs, contract manufacturers, and pivotal trial collaborators seeking high-impact, late-stage development programs.

Collaborative scale Ongoing and announced collaborations with Emmes and upcoming pivotal phase 3 human challenge trials indicate a readiness to engage additional clinical research, data management, and regulatory support partners for large-scale studies.

Regulatory momentum MHRA Innovation Passport designation for BPZE1 and planned global pivotal trials underscore a favorable regulatory environment and potential for consulting, regulatory affairs outsourcing, and market-entry strategy services.

Strategic partnerships Partnerships with hVivo for a world’s first pivotal phase three human challenge trial and a strong publication record position ILiAD as a partner for specialty vaccine development, manufacturing, and access to novel trial platforms.